SHYNDEC(SH:600420) Shang Hai Zheng Quan Bao·2025-10-27 21:49Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., has received approval for its product, Lincomycin Hydrochloride Injection, to pass the consistency evaluation for generic drugs, which is expected to enhance market expansion and sales potential for the product [1][3]. Group 1: Drug Information - The drug Lincomycin Hydrochloride Injection is an antibiotic used for treating severe infections caused by sensitive strains of bacteria such as Streptococcus, Pneumococcus, and Staphylococcus [2]. - The product's sales in public medical institutions in China are projected to be approximately RMB 77.29 million in 2024 [2]. - The cumulative R&D investment for the consistency evaluation of Lincomycin Hydrochloride Injection by China National Pharmaceutical Group Rongsheng is about RMB 3.61 million (unaudited) [2]. Group 2: Company Impact - The approval of Lincomycin Hydrochloride Injection for consistency evaluation is anticipated to positively influence the product's future market expansion and sales [3]. - The current operational performance of the company is not expected to be significantly impacted by this development [3].